Comparison
Hantavirus vs COVID-19: how do they compare?
Both are respiratory viruses, but they are fundamentally different in how they spread, who they affect, and how deadly they are. Hantavirus kills at a far higher rate but cannot spread between people.
The key takeaway
Hantavirus is far more lethal per case (36% vs ~1%) but poses no pandemic risk because it does not spread from person to person. COVID-19 is far less lethal per case but spreads easily between people, which is why it caused a global pandemic. They require completely different prevention strategies.
Side-by-side comparison
Fatality rate
Hantavirus is roughly 36x more lethal per infection, but infects far fewer people.
Person-to-person spread
This is the biggest difference. Hantavirus cannot cause a pandemic because it doesn't spread between people.
How you catch it
Hantavirus requires contact with rodent waste. COVID spreads through normal human interaction.
Incubation period
Hantavirus has a much longer incubation, making it harder to trace the exposure source.
Early symptoms
Early symptoms overlap significantly, which is why hantavirus is often initially misdiagnosed as flu or COVID.
Severe symptoms
HPS progresses much faster. Patients can go from mild cough to respiratory failure in hours.
Vaccine available
Low case numbers make hantavirus vaccine development commercially unviable.
Treatment
COVID treatment has advanced significantly. Hantavirus treatment has not changed in decades.
Annual US cases
Hantavirus is extremely rare. The risk to any individual is very low.
Global pandemic risk
Hantavirus cannot become the next pandemic. Each case is an independent rodent-to-human event.
| Category | Hantavirus | COVID-19 |
|---|---|---|
| Fatality rate | 36% (HPS), 1-15% (HFRS) | ~1% overall (varies by age/variant) |
| Person-to-person spread | No (except Andes virus, rarely) | Yes, highly contagious airborne |
| How you catch it | Inhaling aerosolized rodent urine, droppings, or saliva | Breathing in respiratory droplets from infected people |
| Incubation period | 1 to 8 weeks (average 2-4 weeks) | 2 to 14 days (average 5 days) |
| Early symptoms | Fever, muscle aches, fatigue | Fever, cough, fatigue, loss of taste/smell |
| Severe symptoms | Sudden respiratory failure, lungs fill with fluid | Progressive pneumonia, respiratory distress |
| Vaccine available | No (in the US/Europe) | Yes, multiple vaccines widely available |
| Treatment | Supportive ICU care only, no antiviral | Antivirals (Paxlovid), steroids, supportive care |
| Annual US cases | ~20-40 confirmed HPS cases | Millions (declining with immunity) |
| Global pandemic risk | None (no person-to-person spread) | Already caused a global pandemic |
Common questions
Can hantavirus become the next pandemic?
No. Hantavirus does not spread from person to person (with the rare exception of the Andes virus in South America). Each case requires direct exposure to infected rodent waste. It cannot cause widespread community transmission.
Are the symptoms the same?
Early symptoms overlap: fever, fatigue, muscle aches. But hantavirus progresses to sudden respiratory failure much faster than COVID. COVID more commonly causes cough, sore throat, and loss of taste/smell, which are not typical of hantavirus.
Should I be more worried about hantavirus or COVID?
For most people, COVID poses a greater practical risk simply because exposure is far more likely. Hantavirus risk is concentrated among people who have direct contact with wild rodents or their droppings, particularly in rural western US.